Splenomegaly in myelofibrosis-new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Randhawa, Jasleen ^a   Ostojic, Alen ^b   Vrhovac, Radovan ^b,c   Atallah, Ehab ^a   Verstovsek, Srdan ^d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b KBC Zagreb   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

JAK2 inhibitor; JAK2V617F mutation; Myelofibrosis; Myeloproliferative neoplasms; Splenomegaly

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANAGRELIDE; ANTIANEMIC AGENT; AZACITIDINE; BUSULFAN; CLADRIBINE; CYCLOPHOSPHAMIDE; EVEROLIMUS; HYDROXYUREA; LENALIDOMIDE; LESTAURTINIB; MELPHALAN; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; PACRITINIB; PLACEBO; POMALIDOMIDE; PREDNISONE; RUXOLITINIB; THALIDOMIDE;

ANEMIA; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; HEADACHE; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MYELOFIBROSIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PROGNOSIS; RELAPSE; REMISSION; REVIEW; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT RESPONSE; VOMITING;

HUMANS; JANUS KINASE 2; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; SPLENOMEGALY;

EID: 84864416539     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-43     Document Type: Review

References (52)

1. Myelofibrosis with myeloid metaplasia. Tefferi A, N Engl J Med 2000 342 1255 1265 10.1056/NEJM200004273421706 10781623 (Pubitemid 30235956)
2. The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Hsieh PP, Olsen RJ, O'Malley DP, Konoplev SN, Hussong JW, Dunphy CH, Perkins SL, Cheng L, Lin P, Chang CC, Mod Pathol 2007 20 929 935 10.1038/modpathol.3800826 17643100 (Pubitemid 47271886)
3. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Levine RL, Pardanani A, Tefferi A, Gilliland DG, Nat Rev Cancer 2007 7 673 683 10.1038/nrc2210 17721432 (Pubitemid 47327415)
4. Therapeutic potential of Janus-activated kinase-2 inhibitors for the management of myelofibrosis. Verstovsek S, Clin Cancer Res 2010 16 1988 1996 10.1158/1078-0432.CCR-09-2836 20215535
5. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A, Cancer 2006 107 361 370 10.1002/cncr.22021 16770787 (Pubitemid 44036566)
6. Conventional and Investigational Therapy for Primary Myelofibrosis. Barosi G, Myeloproliferative Neoplasms: Biology and Therapy Humana Press, New York, Verstovsek S, Tefferi A, 2011 117 138 Karp JE (Series Editor): Contemporary Hematology
7. How I treat symptomatic splenomegaly in patients with myelofibrosis. Mesa RA, Blood 2009 113 5394 5400 10.1182/blood-2009-02-195974 19332765
8. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Elliott MA, Chen MG, Silverstein MN, Tefferi A, Br J Haematol 1998 103 505 511 10.1046/j.1365-2141.1998.00998.x 9827926 (Pubitemid 28522460)
9. Control of hypersplenism and painful splenomegaly in myeloid metaplasia by irradiation. Silverstein MN, Int J Radiat Oncol Biol Phys 1977 2 1221 1222 10.1016/0360-3016(77)90137-7 413815 (Pubitemid 8247894)
10. Effective management of accelerated phase myelofibrosis with low-dose splenic radiotherapy. Pardanani A, Brown P, Neben-Wittich M, Tobin R, Tefferi A, Am J Hematol 2010 85 715 716 10.1002/ajh.21799 20661915
11. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Lofvenberg E, Wahlin A, Eur J Haematol 1988 41 375 381 3197824 (Pubitemid 19003754)
12. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Martinez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Diaz-Beya M, Cervantes F, Ann Hematol 2010 89 1233 1237 10.1007/s00277-010-1019-9 20567824
13. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A, Am J Hematol 2008 83 363 365 10.1002/ajh.21149 18266209 (Pubitemid 351614747)
14. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Tefferi A, Barosi G, Mesa RA, Cervantes F, Deeg HJ, Reilly JT, Verstovsek S, Dupriez B, Silver RT, Odenike O, Cortes J, Wadleigh M, Solberg LA, Camoriano JK, Gisslinger H, Noel P, Thiele J, Vardiman JW, Hoffman R, Cross NC, Gilliland DG, Kantarjian H, Blood 2006 108 1497 1503 10.1182/blood-2006-03-009746 16675707 (Pubitemid 44316114)
15. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Mesa RA, Steensma DP, Pardanani A, Li CY, Elliott M, Kaufmann SH, Wiseman G, Gray LA, Schroeder G, Reeder T, Zeldis JB, Tefferi A, Blood 2003 101 2534 2541 10.1182/blood-2002-09- 2928 12517815 (Pubitemid 36857609)
16. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Thapaliya P, Tefferi A, Pardanani A, Steensma DP, Camoriano J, Wu W, Geyer S, Mesa RA, Am J Hematol 2011 86 96 98 10.1002/ajh.21892 21132732
17. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, McClure RF, Giles F, Kantarjian HM, Blood 2006 108 1158 1164 10.1182/blood-2006-02-004572 16609064 (Pubitemid 44232010)
18. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. Quintas-Cardama A, Kantarjian HM, Manshouri T, Thomas D, Cortes J, Ravandi F, Garcia-Manero G, Ferrajoli A, Bueso-Ramos C, Verstovsek S, J Clin Oncol 2009 27 4760 4766 10.1200/JCO.2009.22.6548 19720904
19. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S, Blood 2011 118 899 902 10.1182/blood-2010-12-325589 21622644
20. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA, Leukemia 2007 21 1827 1828 10.1038/sj.leu.2404711 17460705 (Pubitemid 47086775)
21. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, Paquette RL, Cervantes F, Rivera CE, Deeg HJ, Thiele J, Kvasnicka HM, Vardiman JW, Zhang Y, Bekele BN, Mesa RA, Gale RP, Kantarjian HM, J Clin Oncol 2009 27 4563 4569 10.1200/JCO.2008.21.7356 19652059
22. Phase1/-2 study of Pomalidomide in myelofibrosis. Mesa RA, Pardanani AD, Hussein K, Wu W, Schwager S, Litzow MR, Hogan WJ, Tefferi A, Am J Hematol 2010 85 129 130 20052748
23. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Begna KH, Mesa RA, Pardanani A, Hogan WJ, Litzow MR, McClure RF, Tefferi A, Leukemia 2011 25 301 304 10.1038/leu.2010.254 21052089
24. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia. Petti MC, Latagliata R, Spadea T, Spadea A, Montefusco E, Aloe Spiriti MA, Avvisati G, Breccia M, Pescarmona E, Mandelli F, Br J Haematol 2002 116 576 581 10.1046/j.0007-1048.2001.03331.x 11849213 (Pubitemid 34178656)
25. Chemotherapy resolves symptoms and reverses marrow fibrosis in myelofibrosis. Manoharan A, Pitney WR, Scand J Haematol 1984 33 453 459 6515328 (Pubitemid 15180564)
26. Acute leukaemia after busulphan. Stott H, Fox W, Girling DJ, Stephens RJ, Galton DA, British medical journal 1977 2 1513 1517 10.1136/bmj.2.6101.1513 589308 (Pubitemid 8238571)
27. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T, Br J Haematol 2000 110 577 583 10.1046/j.1365-2141.2000.02188.x 10997967
28. Renal cancer after busulphan treatment for chronic myeloid leukemia: therapeutic implications. Foa P, Iurlo A, Maiolo A, Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 1993 4 521 522 (Pubitemid 23211895)
29. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Quintas-Cardama A, Tong W, Kantarjian H, Thomas D, Ravandi F, Kornblau S, Manshouri T, Cortes JE, Garcia-Manero G, Verstovsek S, Leukemia 2008 22 965 970 10.1038/leu.2008.91 18385750 (Pubitemid 351689878)
30. Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. Odenike OM, Godwin JE, Van Besien K, Huo D, Sher D, Burke P, Smith SE, Green M, Melnick J, Wade JL, Lester EP, Klisovic RB, Baer MR, Larson RA, Stock W, Blood [ASH Annual Meeting Abstracts] 2008 112 2809
31. Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia. Faoro LN, Tefferi A, Mesa RA, Eur J Haematol 2005 74 117 120 10.1111/j.1600-0609.2004.00370.x 15654901 (Pubitemid 40175314)
32. Janus kinases in immune cell signaling. Ghoreschi K, Laurence A, O'Shea JJ, Immunol Rev 2009 228 273 287 10.1111/j.1600-065X.2008.00754.x 19290934
33. Myeloproliferative disorders: JAK2 and beyond. Verstovsek S, The American Society of Clinical Oncology The American Society of Clinical Oncology, The American Society of Clinical Oncology The American Society of Clinical Oncology, American Society of Clinical Oncology 2011 Educational Book The American Society of Clinical Oncology, Alexandria, VA 2011 256 261
34. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Lancet 2005 365 1054 1061 15781101 (Pubitemid 40386783)
35. A gain-of-function mutation of JAK2 in myeloproliferative disorders. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC, N Engl J Med 2005 352 1779 1790 10.1056/NEJMoa051113 15858187 (Pubitemid 40570926)
36. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG, Cancer cell 2005 7 387 397 10.1016/j.ccr.2005.03.023 15837627 (Pubitemid 40544655)
37. Oncogenic mechanisms in myeloproliferative disorders. Delhommeau F, Pisani DF, James C, Casadevall N, Constantinescu S, Vainchenker W, Cell Mol Life Sci 2006 63 2939 2953 10.1007/s00018-006-6272-7 17131059 (Pubitemid 46072300)
38. Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC, Blood 2006 108 1377 1380 10.1182/blood-2005-11-009605 16675710 (Pubitemid 44232040)
39. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Mesa RA, Hematology Am Soc Hematol Educ Program 2007 355 362
40. FDA approves first drug to treate a rare bone marrow disease, [ http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280102.htm ]
41. Therapeutic potential of JAK2 inhibitors. Verstovsek S, Hematology Am Soc Hematol Educ Program 2009 636 642
42. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A, N Engl J Med 2010 363 1117 1127 10.1056/NEJMoa1002028 20843246
43. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM, N Engl J Med 2012 366 799 807 10.1056/NEJMoa1110557 22375971
44. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G, N Engl J Med 2012 366 787 798 10.1056/NEJMoa1110556 22375970
45. Efficacy of TG101348, a selective JAK2 Inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Wernig G, Kharas MG, Okabe R, Moore SA, Leeman DS, Cullen DE, Gozo M, McDowell EP, Levine RL, Doukas J, Mak CC, Noronha G, Martin M, Ko YD, Lee BH, Soll RM, Tefferi A, Hood JD, Gilliland DG, Cancer cell 2008 13 311 320 10.1016/j.ccr.2008.02.009 18394554 (Pubitemid 351446195)
46. TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Lasho TL, Tefferi A, Hood JD, Verstovsek S, Gilliland DG, Pardanani A, Leukemia 2008 22 1790 1792 10.1038/leu.2008.56 18354492
47. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, Stone RM, Silverman MH, Gilliland DG, Shorr J, Tefferi A, J Clin Oncol 2011 29 789 796 10.1200/JCO.2010.32.8021 21220608
48. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS, Blood 2010 116 4436 4438 10.1182/blood-2010-05-287417 20651074
49. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. Pardanani AD, Caramazza D, George G, Lasho TL, Hogan WJ, Litzow MR, Begna K, Hanson CA, McClure RF, Bavisotto LM, Smith G, Kowalski M, Sirhan S, Roberts AW, Gupta V, Gotlib J, Tefferi A, J Clin Oncol 2011 29 suppl; abstr 6514 422s
50. Results of a phase 2 study of pacritinib (SB1518), a novel oral JAK2 inhibitor, in patients with primary, post-polycythemia vera, and post-essential thrombocythemia myelofibrosis. Komrokji RS, Wadleigh M, Seymour JF, Roberts AW, To LB, Zhu HJ, Mesa R, To LB, Zhu HJ, Mesa RA, Blood 2011 118 Abstract 282 21937696
51. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, Kennedy D, Estrov Z, Cortes J, Verstovsek S, Blood 2010 115 1131 1136 10.1182/blood-2009-10-246363 20008298
52. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Guglielmelli P, Barosi G, Rambaldi A, Marchioli R, Masciulli A, Tozzi L, Biamonte F, Bartalucci N, Gattoni E, Lupo ML, Finazzi G, Pancrazzi A, Antonioli E, Susini MC, Pieri L, Malevolti E, Usala E, Occhini U, Grossi A, Caglio S, Paratore S, Bosi A, Barbui T, Vannucchi AM, investigators AI-GIMM, Blood 2011 118 2069 2076 10.1182/blood-2011-01-330563 21725052